Business
Mesoblast holds out hope for heart failure drug – Sydney Morning Herald
Shares in the stem cell treatment developer regained some ground after a horror end to 2020.
Shares in stem cell biotech Mesoblast jumped nearly 16 per cent after the company said it would pursue approval for its key heart failure drug in the US despite a clinical trial delivering mixed results.
On Monday the company told investors that additional data from the phase 3 trial of its Revascor product showed a “substantial and durable reductions in heart attacks, strokes and cardiac deaths” in patients with chronic heart failure.
Mesoblast shares bounced after a tough end to 2020, when shares…
-
Noosa News20 hours agoKatter and pregnant wife crash-land plane in outback Qld
-
Noosa News20 hours agoFollowing Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’
-
Business21 hours ago16 ASX 200 shares roar to multi-year highs amid new market milestone
-
Business9 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?